Probiotic therapy of intestinal inflammation and infections

Current Opinion in Gastroenterology

Volumn 21, Issue 1, 2005, Pages 44-50

  Sartor, R Balfour ^a,b  

^a Depts Med Microbiol and Immunol   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Colitis; Crohn disease; Intestinal infection; Intestinal inflammation; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOSUPPRESSIVE AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT;

BACTERIAL GROWTH; BACTERIAL INFECTION; BIFIDOBACTERIUM; CELL ADHESION; CELL INVASION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLLAGENOUS COLITIS; CROHN DISEASE; DIARRHEA; DRUG MECHANISM; DRUG SYNTHESIS; ENTERITIS; ESCHERICHIA COLI; GASTROINTESTINAL INFECTION; GENETIC ENGINEERING; GROWTH INHIBITION; HUMAN; ILEITIS; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LACTOBACILLUS; NONHUMAN; ORAL REHYDRATION THERAPY; PATHOGENESIS; PROTOZOAL INFECTION; RECURRENT DISEASE; REHYDRATION; REMISSION; REVIEW; STREPTOCOCCUS SALIVARIUS; SURFACE PROPERTY; TREATMENT OUTCOME; ULCERATIVE COLITIS; VIRUS INFECTION;

ANIMALS; BIFIDOBACTERIUM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ESCHERICHIA COLI; GASTROENTERITIS; HUMANS; LACTOBACILLUS; PROBIOTICS; STREPTOCOCCUS;

EID: 13244275284     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Sartor RB: Microbial influences in inflammatory bowel diseases: role in pathogenesis and clinical implications. In Kirsner's Inflammatory Bowel Diseases, edn 6. Edited by Sartor RB, Sandborn WJ. Elsevier Publishers; 2004:138-162.
2. Schultz M, Scholmerich J, Rath HC: Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. Dig Dis 2003, 21:105-128. This is a thoughtful review of this topic with an extensive list of references by experienced investigators.
3. Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics and prebiotics. Gastroenterology 2004, 126:1620-1633. This is a recent comprehensive review of the clinical efficacy of various probiotic agents in IBD, with particular attention to the rationale, results of clinical trials, and mechanisms of action.
4. Gionchetti P, Amadini C, Rizzello F, et al.: Probiotics for the treatment of postoperative complications following intestinal surgery. Best Pract Res Clin Gastroenterol 2003, 17:821-831.
5. Shanahan F: Probiotics: a perspective on problems and pitfalls. Scand J Gastroenterol Suppl 2003, 237:34-36.
6. Floch MH: Probiotics, irritable bowel syndrome, and inflammatory bowel disease. Curr Treat Options Gastroenterol 2003, 6:283-288.
7. Tamboli CP, Caucheteux C, Cortot A, et al.: Probiotics in inflammatory bowel disease: a critical review. Best Pract Res Clin Gastroenterol 2003, 17:805-820. This is another thoughtful, comprehensive review of evidence supporting this therapeutic approach in IBD.
8. Fedorak RN, Madsen KL: Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:286-299.
9. Kruis W: Antibiotics and probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20(suppl 4):75-78.
10. Famularo G, Mosca L, Minisola G, et al.: Probiotic lactobacilli: a new perspective for the treatment of inflammatory bowel disease. Curr Pharm Des 2003, 9:1973-1980.
11. Allen SJ, Okoko B, Martinez E, et al.: Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004, 2:CD003048. This is a complete and thoughtful analysis of 23 published trials of 1917 subjects that provides a comprehensive view of the current status of this field.
12. Gill HS: Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2003, 17:755-773.
13. Kruis W, Kalk EK, Fric P, et al.: Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine [abstract]. Gastroenterology 2001, 120:A127.
14. Cui HH, Chen CL, Wang JD, et al.: Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004, 10:1521-1525.
15. Guslandi M, Giollo P, Testoni PA: A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003, 15:697-698.
16. Fedorak RN, Gionchetti P, Campieri M, et al.: VSL3 probiotic mixture induces remission in patients with active ulcerative colitis [abstract]. Gastroenterology 2003, 124:A377.
17. Borody TJ, Warren EF, Leis S, et al.: Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003, 37:42-47.
18. Mimura T, Rizzello F, Helwig U, et al.: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108-114. This report confirms the original observation that combination probiotic therapy can dramatically decrease the recurrence of persistently relapsing pouchitis after induction of remission with antibiotic treatment.
19. Gionchetti P, Rizzello F, Helwig U, et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo controlled trial. Gastroenterology 2003, 124:1202-1209. This is a novel observation that administering VSL 3 at the time of restoring bowel continuity significantly decreased the onset of clinically detected pouchitis in 40 patients studied in a prospective, placebo-controlled, blinded fashion.
20. Gosselink MP, Schouten WR, van Lieshout LM, et al.: Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004, 47:876-884.
21. Kuisma J, Mentula S, Jarvinen H, et al.: Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003, 17:509-515.
22. Laake KO, Line PD, Aabakken L, et al.: Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol 2003, 38:409-414.
23. Schultz M, Timmer A, Herfarth HH, et al.: Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004, 4:5.
24. Tromm A, Niewerth U, Khoury M, et al.: The probiotic E. coli strain Nissle 1917 for the treatment of collagenous colitis: first results of an open-label trial. Z Gastroenterol 2004, 42:365-369.
25. Sartor RB: Animal models of intestinal inflammation. In Kirsner's Inflammatory Bowel Diseases, edn 6. Edited by Sartor RB, Sandborn WJ. Elsevier Publishers; 2004:120-137.
26. Osman N, Adawi D, Ahrne S, et al.: Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dig Dis Sci 2004, 49:320-327.
27. Araki Y, Andoh A, Takizawa J, et al.: Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats. Int J Mol Med 2004, 13:577-580.
28. Akisu M, Baka M, Yalaz M, et al.: Supplementation with Saccharomyces boulardii ameliorates hypoxia/reoxygenation-induced necrotizing enterocolitis in young mice. Eur J Pediatr Surg 2003, 13:319-323.
29. McCarthy J, O'Mahony L, O'Callaghan L, et al.: Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003, 52:975-980.
30. Schultz M, Munro K, Tannock GW, et al.: Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats. Clin Diagn Lab Immunol 2004, 11:581-587.
31. Hoentjen F, Zhang X, Tannock GW, et al.: The prebiotic combination inulin and oligofructose prevents colitis in HLA-B27 transgenic rats [abstract]. Can J Gastroenterol 2004, 18:66A.
32. Dieleman LA, Goerres MS, Arends A, et al.: Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003, 52:370-376.
33. Sheil B, McCarthy J, O'Mahony L, et al.: Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 2004, 53:694-700.
34. Rachmilewitz D, Katakara K, Karmeli F, et al.: Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004, 126:520-528. This paper presents elegantly developed evidence that bacterial DNA can prevent and treat acute experimental colitis by stimulating a protective immune response that requires signaling through toll-like receptor-9 and MyD88.
35. Jijon HB, Backer J, Diaz H, et al.: DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004, 126:1358-1373. This combined in vivo and in vitro study showed that VSL 3 DNA selectively blocks NFκB activation and bacterially induced proinflammatory molecule production, as well as inhibits experimental colitis in IL-10-deficient mice.
36. Steidler L, Hans W, Schotte L, et al.: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352-1355.
37. Vandenbroucke K, Hans W, Van Huysse J, et al.: Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004, 127:502-513.
38. Surawicz CM: Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Pract Res Clin Gastroenterol 2003, 17:775-783. This is an excellent review of the ability of probiotics to prevent and treat diarrhea after antibiotic therapy, in the presence or absence of C. difficile toxin.
39. Wullt M, Hagslatt ML, Odenholt I: Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003, 35:365-367.
40. Plummer S, Weaver MA, Harris JC, et al.: Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004, 7:59-62.
41. Erdeve O, Tiras U, Dallar Y: The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr 2004, 50:234-236.
42. La Rosa M, Bottaro G, Gulino N, et al.: Prevention of antibiotic-associated diarrhea with Lactobacillus sporogens and fructo-oligosaccharides in children. A multicentric double-blind vs placebo study. Minerva Pediatr 2003, 55:447-452.
43. Hopkins MJ, Macfarlane GT: Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol 2003, 69:1920-1927.
44. Salazar-Lindo E, Miranda-Langschwager P, Campos-Sanchez M, et al.: Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: a randomized, double-blind, placebo controlled clinical trial. BMC Pediatr 2004, 4:18.
45. Sudarmo SM, Ranuh RG, Rochim A, et al.: Management of infant diarrhea with high-lactose probiotic-containing formula. Southeast Asian J Trop Med Public Health 2003, 34:845-848.
46. Sazawal S, Dhingra U, Sarkar A, et al.: Efficacy of milk fortified with a probiotic Bifidobacterium lactis (DR-10TM) and prebiotic galacto- oligosaccharides in prevention of morbidity and on nutritional status. Asia Pac J Clin Nutr 2004, 13:328. This is a large, prospective study of supplementing the diet of 634 young children in south Delhi with a milk-based combination of a probiotic and prebiotic for 1 year. This treatment significantly improved health and decreased dysentery.
47. Duggan C, Penny ME, Hibberd P, et al.: Oligofructose-supplemented infant cereal: 2 randomized, blinded, community-based trials in Peruvian infants. Am J Clin Nutr 2003, 77:937-942.
48. Cong Y, Konrad A, Iqbal N, et al.: Probiotics and immune regulation of inflammatory bowel diseases. Curr Drug Targets Inflamm Allergy 2003, 2:145-154.